A Phase 3 Study to Evaluate Weight Gain of ALKS 3831 Compared to Olanzapine in Adults With Schizophrenia

Trial Profile

A Phase 3 Study to Evaluate Weight Gain of ALKS 3831 Compared to Olanzapine in Adults With Schizophrenia

Recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs Olanzapine/samidorphan (Primary) ; Olanzapine
  • Indications Schizophrenia
  • Focus Registrational; Therapeutic Use
  • Acronyms ENLIGHTEN-2
  • Sponsors Alkermes plc
  • Most Recent Events

    • 04 May 2017 According to an Alkermes plc media release, data from this trial are expected in mid-2018.
    • 28 Mar 2016 Study design will be presented at the 5th Biennial Schizophrenia International Research Society (SIRS) Conference 2016, according to an Alkermes plc media release.
    • 10 Feb 2016 Status changed from planning to recruiting, according to an Alkermes plc media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top